Strategies for the Management of Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Strategies for the Management of Rheumatoid Arthritis

Published:2012-02 Issue:2 Volume:35 Page:125-130
ISSN:0147-7447
Container-title:Orthopedics
language:en
Short-container-title:Orthopedics

Author:

Wilkie W.S.,Schwieterman Philip

Publisher

SLACK, Inc.

Subject

Orthopedics and Sports Medicine,Surgery

Reference28 articles.

1. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I

2. Rheumatoid Arthritis

3. Extra-articular manifestations and complications of rheumatoid arthritis

4. Work disability in rheumatoid arthritis 10 years after the diagnosis;Sokka T;J Rheumatol,1999

5. Benefit/risk of therapies for rheumatoid arthritis:underestimation of the “side effects” or risks of RA leads to underestimation of the benefit/risk of therapies;Pincus T;Clin Exp Rheumatol,2004

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The protective effects of allopurinol against IL-17A-induced inflammatory response in mast cells;Molecular Immunology;2022-01

2. Emerging Therapeutic Effects of Herbal Plants in Rheumatoid Arthritis;Endocrine, Metabolic & Immune Disorders - Drug Targets;2021-05-04

3. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib;The Journal of Clinical Pharmacology;2019-08-25

4. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis;Expert Review of Clinical Pharmacology;2019-05-13

5. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials;Clinical Pharmacokinetics;2017-10-26